Omalizumab treatment of moderate to severe asthma in the adolescent and pediatric population

Lignende værker

• Xolair® (omalizumab) enrollment in a tertiary care allergy and asthma clinic in Canada
  af: Cameron, Jodi, et al.
  Udgivet: (2014)
• Omalizumab is effective in the treatment of difficult-to-treat chronic spontaneous urticaria
  af: Forgie, Jennifer, et al.
  Udgivet: (2014)
• The observed incidence of anaphylaxis and serum sickness in patients receiving omalizumab in a tertiary allergy and asthma clinic in Canada
  af: MacRae, Megan, et al.
  Udgivet: (2014)
• Use of Omalizumab to treat a nine-year old, with steroid-dependent, allergic asthma, adrenal insufficiency and vertebral compression fractures due to steroid induced severe osteoporosis
  af: Ring, Alicia, et al.
  Udgivet: (2011)
• Treatment of moderate to severe pediatric asthma Omalizumab and potential future use of monoclonal antibodies
  af: Wright, Lakiea S., et al.
  Udgivet: (2016)